UNSPSC 51282924: Ibafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C15H14FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53VPK9R0T5, chemically known as 9-fluoro-6,7-dihydro-5,8-dimethyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylic acid but generally known as ibafloxacin, which bears US NIH Compound Identifier 71186. European Medicines Agency schedules Ibafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08091MIG.

UNSPSC 51282924 Ibafloxacin, a Commodity code, shows limited direct recent activity; state and local governments procuring under this specific code are currently buying generic pharmaceuticals and OTC products through cooperative purchasing vehicles and direct government health agency contracts, rather than ibafloxacin as a discrete line item. The recent opportunities tagged to this code reflect broader pharmaceutical procurement patterns: state health agencies and local government health departments source generic multi-source drugs and emergency medical supplies through established wholesaler networks, cooperative purchasing alliances, and direct manufacturer relationships. Issuing bodies include state health departments (Texas HHS Commission), county health agencies (Seminole County, Florida), municipal fire and rescue departments (City of Tampa), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). The mix reflects decentralized procurement across state agencies, counties, and cities managing separate health, emergency response, and pharmacy benefit programs.

Geographic activity centers on Florida, Texas, and Minnesota, with broader participation through multistate cooperative purchasing reaching Oregon and other allied jurisdictions. Representative recent opportunities include the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (response due March 26, 2026), which establishes multiple contracts through authorized wholesalers with pricing weighted 75 percent on competitiveness and compliance with cGMP and Drug Supply Chain Security Act requirements; Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023), soliciting 1,900 units of naloxone and 800 deactivation systems annually for quarterly delivery to county health facilities; and the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026), a sheltered market procurement set aside for certified Small Local Business Enterprises with an estimated contract value of $700,000. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) signals emerging state interest in alternative pharmacy benefit contracting models beyond traditional PBM arrangements.